Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures
United European Gastroenterology Journal · 2025-12 · 13 (10) · 1905-1912
DOI: 10.1002/ueg2.70124 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift United European Gastroenterology Journal, online erschienen am 08.10.2025. Verfasst von Brice Chanez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Precision Medicine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut National Du Cancer, Canceropôle Provence-Alpes-Côte d'Azur, Fondation ARC pour la Recherche sur le Cancer.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, with chemotherapy as the mainstay but highly variable efficacy and toxicity. Current regimens, such as FOLFIRINOX and gemcitabine‐based combinations, are selected empirically without validated biomarkers to guide choice. Several strategies have been explored to personalize therapy. Patient‐derived organoids and molecular classifiers such as PurIST have improved biological understanding but have limited clinical applicability. More recently, predictive transcriptomic signatures have emerged as practical tools. GemPred identifies patients likely to benefit from adjuvant gemcitabine; GemCore , validated in both resected and metastatic tumors, is compatible with small biopsies; and Pancreas‐View integrates multiple drug‐specific predictors, including for all FOLFIRINOX components and gemcitabine, enhanced by AI. These approaches, retrospectively validated in large cohorts and clinical trials, consistently link predicted sensitivity with improved survival. Beyond regimen selection, signatures enable treatment de‐escalation, optimize first‐line choices, and identify multidrug‐resistant tumors. Ongoing prospective trials will establish their feasibility, supporting transcriptomic profiling as a step toward precision chemotherapy in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
- Department of Medical Oncology, Institut Paoli-Calmettes, Paoli-Calmettes Institute, Marseille, France.
- Department of Medical Oncology, Institut Curie, Versailles-Saint Quentin University, Saint-Cloud, France.
- Hospital de Alta Complejidad El Cruce, Florencio Varela, Buenos Aires, Argentina.
- University Arturo Jauretche, Florencio Varela, Buenos Aires, Argentina.
ORCID-Profile: Juan Iovanna, Nelson Dusetti
Förderung
- Institut National Du Cancer
- Canceropôle Provence-Alpes-Côte d'Azur
- Fondation ARC pour la Recherche sur le Cancer
- Institut National de la Santé et de la Recherche Médicale
- Ligue Contre le Cancer
- Viatris
- Canceropôle Provence-Alpes-Côte d’Azur
Zitieren
APA
Chanez, B., Delaye, M., Fraunhoffer, N., Iovanna, J., Neuzillet, C., & Dusetti, N. (2025). Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. United European Gastroenterology Journal, 13(10), 1905-1912. https://doi.org/10.1002/ueg2.70124
Vancouver
Chanez B, Delaye M, Fraunhoffer N, Iovanna J, Neuzillet C, Dusetti N. Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. United European Gastroenterology Journal. 2025;13(10):1905-1912. doi:10.1002/ueg2.70124
BibTeX
@article{Chanez2025,
author = {Chanez, Brice and Delaye, Matthieu and Fraunhoffer, Nicolas and Iovanna, Juan and Neuzillet, Cindy and Dusetti, Nelson},
title = {Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures},
journal = {United European Gastroenterology Journal},
year = {2025},
volume = {13},
number = {10},
pages = {1905--1912},
doi = {10.1002/ueg2.70124}
}
EUVIMED